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Objectives: To assess the economic burden and health care resource utili-
zation among patients in long-term care facilities who were diagnosed with 
stroke. MethOds: Patients diagnosed with stroke (International Classification of 
Diseases, 9th Revision, Clinical Modification diagnosis codes 433, 434 and 436) were 
identified using the Long Term Care Minimum Data Set (MDS) linked to 5% Medicare 
data from 01JAN2009 through 31DEC2010. The initial diagnosis date was designated 
as the index date. Patients without a stroke diagnosis (control cohort) were matched 
to stroke patients, and 1:1 propensity score matching (PSM) was used to control for 
age, region, gender and baseline Charlson Comorbidity Index score. The index date 
for the control cohort was randomly chosen to reduce selection bias. Patients in 
both cohorts were required to be age ≥ 65 years, have at least two consecutive quar-
terly assessments documented in MDS data 6 months prior to the index date and 
have continuous medical and pharmacy benefits 1 year before and after the index 
date. Results: Once PSM was applied, 1,014 patients were included in each cohort, 
and baseline characteristics were balanced. A higher percentage of stroke patients 
had inpatient admissions (40.34% vs. 23.37%, p< 0.0001), outpatient visits (92.31% 
vs. 89.45%, p= 0.0253), skilled nursing facility (SNF; 37.67% vs. 28.21%, p< 0.0001) and 
durable medical equipment (DME) claims (30.47% vs. 22.09%, p< 0.0001) than those 
in the control cohort. Stroke patients also incurred considerably higher inpatient 
($7,068 vs. $3,418, p< 0.0001), outpatient ($3,545 vs. $2,539, p< 0.0001), SNF ($8,036 vs. 
$3,695, p< 0.0001), DME ($394 vs. $235, p= 0.0023) and carrier claim costs ($3,606 vs. 
$2,489, p< 0.0001) than those without a stroke diagnosis. cOnclusiOns: Patients 
diagnosed with stroke had considerably higher health care resource utilization and 
costs than those in the control cohort.
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Objectives: To assess the economic burden of the management of hypertension 
and diabetes in two tertiary health facilities in Bayelsa State, Niger Delta, South-
south Nigeria. MethOds: It is a retrospective review of randomly selected case 
notes of 531 hypertensive and diabetic patients. The demographics and cost of 
medicines prescribed were reviewed based on the hospital prices. These patients 
were randomly selected from those who attended the endocrinology and cardiol-
ogy clinics of the health facilities in 2011 and 2012. Results: Mean patients’ age 
was 55.70±12.23 years. Most (42.2%) of them were civil servants while the rest were 
petty business owners (26.6%), retired workers (14.9%), farmers (10.3%), or unem-
ployed (6%). The monthly average costs of all prescribed medications per patient 
for initiation and maintenance of therapy were ₦3333.43±2317.40 (US$18.17±12.60) 
and ₦4458.09±3064.8 (US$24.30±16.70) respectively (p < 0.05). Diuretics and sulpho-
nylureas were the most economical of all the drugs prescribed monthly per patient 
accounting for ₦531.70 [US$2.90] and ₦559.10 [US$3.10] respectively for initiation 
of therapy, and ₦768.1 [US$4.20] and ₦631.1 [US$3.40] for maintenance of therapy. 
However, the most expensive of all the medicines were angiotensin receptor blockers 
which accounted for ₦4,368.8 [US$23.8] for initiation and ₦4,810.50 [US$26.20] for 
maintenance of therapy as well as insulins (at ₦2,448.20 [US$13.30] for initiation 
and ₦2,457.10 [US$13.40] for maintenance of therapy). cOnclusiOns: Considering 
the poverty level in the Niger Delta region of Nigeria, the medication cost burden 
of managing hypertension and diabetes is high and unaffordable by most of the 
patients.
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Objectives: Giant cell arteritis (GCA), a chronic vasculitis commonly presenting 
with headache, affects approximately 230,000 individuals in the US. However, lim-
ited data exist on the health care resource utilization and costs that are attributable 
to GCA. The objective of this study was to estimate the cost of illness in patients with 
GCA in the US. MethOds: A retrospective cohort of patients with a new diagnosis 
of GCA and five matched controls was identified from a large US claims database 
between January 1st 2008 and December 31st2011. Newly diagnosed GCA patients 
were defined by a diagnosis of GCA (ICD-9 446.5) during the study period and no GCA 
diagnosis in the 12 months prior. Controls were defined by absence of a GCA diag-
nosis. GCA patients and controls were matched on age, gender, region, index year of 
diagnosis, and index month of diagnosis. One-year healthcare costs were compared 
among cases and controls, adjusting for age, gender, Charlson Comorbidity Index 
(CCI), chronic disease count, U.S. region, health plan type (HMO vs. other), and year 
using generalized linear models. Results: A cohort of 11,245 GCA patients and 
56,230 controls was identified. The mean age of the cohort was 70 years and 71% 
were females. Mean CCI was 1.6 for GCA patients and 0.8 for controls. Mean one-
year cost for GCA patients was $26,400 (SD: $48,500) and mean one-year cost for 
controls was $11,500 (SD: $29,200). After multivariate adjustment, the difference 
in one-year cost between GCA patients and controls was $4,800 (95% CI: $4,080—
$5,520). cOnclusiOns: Patients with GCA experience increased healthcare costs 
compared to patients without GCA after adjusting for covariates related to health 
care resource utilization and costs. Our results are the first to inform researchers, 
clinicians, and policymakers on the cost burden of GCA, estimated to be approxi-
mately $1 billion annually in the US.
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simulations were performed to propagate the uncertainty of parameters. Results: 
The expected cost (and its credibility intervals of 95%) of the prevalent popula-
tion with AH, DM and dyslipidemia using prices from public health system 
was in Chilean pesos (CLP$) CLP$12,463MM (CLP$11,394MM – CLP$13,622MM), 
CLP$36,425MM (CLP$25,603MM – CLP$49,624MM) and CLP$20,658MM (CLP$11,090MM 
– CLP$33,284MM) respectively. While, the estimated cost based on private health 
system was CLP$700,613MM (CLP$561,764MM – CLP$865,354MM), CLP$333,921MM 
(CLP$253,963MM – CLP$436,879MM) and CLP$680,919MM (CLP$327,916MM – 
CLP$1,645,906MM) respectively. cOnclusiOns: The expected cost needed for the 
treatment of the three conditions studied represent 1.3% and 2.9% in the worst case 
scenario (33% considering private system prices) of the 2014 health budget, and the 
effort to improve the subdiagnostic of these conditions would determine a budget 
impact of at least 0.86%, only with pharmacological treatment.
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Objectives: Systemic arterial hypertension (SAH) is a chronic condition, and 
despite the large number of available antihypertensive drugs, patients with SAH 
who are drug-treated frequently do not obtain goal Blood Pressure (BP) levels. A 
combination of drugs is recommended for those cases, however, compliance is 
improved when agents are prescribed as fixed dose combinations rather than sepa-
rate pills. A combination of bisoprolol and amlodipine once a day showed a rapid 
reduction of BP after 4 weeks. The aim of this paper is to perform cost-effectiveness 
(CE) and budget impact (BI) analyses of Concor® AM compared to amlodipine + 
bisoprolol as separate tablets. MethOds: A daily-cycle markov model was built 
considering the outcomes: days on treatment; number of events (stroke, myocardial 
infarction, heart failure and angina); number of full-lifetime-patients with transitory 
drug interruption (non-compliance); number of full-lifetime-patients with normal 
blood pressure and days of life. Efficacy data were obtained from literature review 
and unit costs were obtained from official price lists. The time horizon of the CE 
and BI model was 30 and 10 years, respectively. A 5% annual discount rate was 
applied in costs and benefits in the CE model. Results: Concor® AM increased 
overall survival in 43 days and assured more 2,090 days on treatment, per patient, 
during lifetime period. Also, reduced 183 events, and allowed more 187 patients 
with controlled blog pressure, per 1,000 patients. Concor® AM was dominant vs. 
Concor + Amlodipine, resulting in financial resource saving of approximately 8.1% 
(BRL 5,720.72 per patient). Additionally, the use of Concor® AM in patients with 
SAH resulted in financial resource saving of approximately BRL 300,321,412.45, in 
the period from 2014 to 2025. cOnclusiOns: Fixed-dose combinations such as 
Concor-AM do represent an opportunity to increase compliance and consequently 
health outcomes and its costs.
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Objectives: The objective of this study was to estimate the overall differences 
in medical costs when nonvalvular atrial fibrillation and venous thromboembo-
lism (VTE) patients are treated with each of the new oral anticoagulants (NOACs), 
dabigatran, rivaroxaban, apixaban, and edoxaban vs. warfarin. MethOds: Medical 
cost differences associated with NOAC use for patients treated for NVAF and acute 
VTE were obtained from previous publications and were based on clinical event 
rates from clinical trials. The medical cost differences associated with edoxaban 
vs. warfarin among NVAF patients were estimated as done previously for other 
NOACs. A hypothetical health plan population with 1 million members was used to 
estimate and compare the medical cost differences associated with use of each of 
the NOACs vs. warfarin among the combined NVAF and VTE populations. Prevalence 
rates of NVAF and VTE were derived from published literature. The same hypotheti-
cal usage rate (i.e. 10%) for each NOAC was assumed to facilitate the comparison of 
the medical cost differences. The medical cost differences of NOACs vs. warfarin 
were projected in the years 2015-2018. Results: In 2014, in a hypothetical popula-
tion of 1 million health plan members, medical costs were estimated to be reduced 
by the greatest amount for NVAF and VTE patients treated with apixaban ($11.5 
million), followed by those treated with edoxaban ($6.6 million), rivaroxaban ($4.2 
million), and dabigatran ($3.7 million). Medical cost savings associated with use of 
any of the NOACs were projected to increase from 2014 to 2018. cOnclusiOns: 
Based on our economic analysis using clinical trial data, treatment of patients with 
NVAF and VTE with any of the NOACs instead of warfarin is associated with sav-
ings in medical costs, with apixaban being associated with the greatest savings in 
medical costs. The direct application of the results to the real-world setting will 
require further assessment.
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Objectives: Giant cell arteritis (GCA) is the most frequent primary large-vessel 
vasculitis in patients aged over 50 years. Common early manifestations include 
constitutional symptoms, headache, visual loss, polymyalgia rheumatica (PMR), and 
jaw claudication. The incidence increases with age and is higher in populations of 
Northern European origin than in those of Mediterranean countries. The incidence 
of GCA in France is 10 to 20 per 100 000 people older than 50 years. The aim of this 
study is to assess the net costs due to GCA in France and to identify driver costs of 
this disease. MethOds: This retrospective study used an incidence based approach. 
Incident GCA patients were identified in the French National Health Insurance 
System database (SNIIR-AM) from 2005 to 2008. For each case, 6 disease-free age 
and gender matched-controls were randomly selected. Their resources consump-
tion was recorded over a 5 years period. Costs were estimated from the health 
insurance perspective. Direct medical, non-medical and indirect costs (i.e. daily 
benefits) were recorded. GCA patient’s costs were compared to control’s costs then 
we calculated GCA net costs. Results: 103 GCA patients and 606 control patients 
were included. In the first year following the diagnosis, GCA patient’s costs were 
8,139€ and control’s costs were 3,661€ (p< 0.001), the net GCA costs was 4,478€ . 
This incremental cost was mainly due to inpatients, medications and paramedical 
costs which accounted for 40%, 17% and 16%, respectively. GCA and controls costs 
decreased during the 5 year follow-up period from 8,139€ year one to 4,572€ year 
five for GCA and from 3,661€ to 3,054€ for controls. cOnclusiOns: GCA constitutes 
a huge economic burden in health insurance expenses.
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Objectives: Chronic heart failure (CHF) is a progressive, debilitating disease where 
the heart is unable to pump enough blood throughout the body. In a recent trial, 
LCZ 696, a novel combination drug, showed significantly reduced mortality and 
heart failure hospitalisations compared with enalapril for the treatment of patients 
with CHF. The objective of this study was to systematically identify and quantify 
the non-health sector costs for adults with CHF and in caregivers to patients with 
CHF. MethOds: Embase, Medline, Cochrane Library and relevant conferences and 
HTA databases were searched systematically in July 2014 to identify articles contain-
ing CHF populations with any data on indirect or direct cost/resource use that did 
not fall on the health care budget was collected. There was no restriction on inter-
vention or comparator. Results: In total, seven studies were identified that met the 
inclusion criteria of the review. Three studies reported direct costs that do not fall 
on the health care budget and two studies reported indirect costs incurred by heart 
failure patients and their caregivers. No studies could be considered generalizable 
to the UK perspective. The societal cost evidence identified in this review included 
patient out-of-pocket expenses (US, Brazil, Taiwan, Spain), number of work days 
lost for patients (US, Brazil), hours of care provided from informal caregivers (Iran, 
Spain, Taiwan, Australia), and sick leave (US, Brazil) associated with hospitalization 
for heart failure events. Only scarce information pertaining to direct non-health 
care sector costs (caregiver time and patient out-of-pocket expenses), and indirect 
effects on the rest of the economy (sick leave, attendee and patient working days 
lost) were reported. cOnclusiOns: In summary, this review highlights the paucity 
of available societal cost evidence for patients with chronic heart failure. Further 
studies are needed to address this knowledge gap.
PCV58
long-tErm EConomiC BurdEn assoCiatEd with CardioVasCular 
EVEnts among high-risk PatiEnts with hyPErliPidEmia
Fox K.M.1, Wang L.2, Gandra S.R.3, Quek R.G.W.3, Li L.2, Baser O.4
1Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 2STATinMED Research, Plano, TX, USA, 
3Amgen, Inc., Thousand Oaks, CA, USA, 4STATinMED Research, The University of Michigan, MEF 
University, Ann Arbor, MI, USA
Objectives: This study evaluated the economic burden associated with new car-
diovascular events (CVEs) for 3 years post-CVE among high-risk patients diagnosed 
with hyperlipidemia. MethOds: A retrospective cohort study was conducted 
among high-risk hyperlipidemic patients with and without a new CVE, using IMS 
LifeLink PharMetrics Plus data 01/01/2006-06/30/2012. CVEs included primary inpa-
tient claims for myocardial infarction, unstable angina, ischemic stroke, transient 
ischemic attack, revascularization and heart failure. Patients were assigned to 
risk cohorts based on history of CVE and coronary heart disease risk equivalent 
(CHD RE) condition. Propensity score matching was applied to compare healthcare 
costs among patients with and without new CVEs, ranging from 1 month (acute 
phase) to 3 years post-CVE date. Results: A total of 21,482 matched patients 
were included in the history of CVE cohort and 181,228 in the CHD RE cohort. 
Hyperlipidemic patients with new CVEs were, on average, aged 65-72 years, both 
cohorts had 65.2% male and 74.7-84.4% had hypertension (most common baseline 
comorbidity). Total costs per patient per month (PPPM) were significantly higher 
among patients with versus without new CVEs during the acute phase (history of 
CVE: $27,247 vs. $1,586; CHD RE: $30,742 vs. $914; p< 0.0001) and remained higher 
during years 1, 2 and 3, respectively, post-CVE among patients in the history of CVE 
cohort ($2,603 vs. $1,252; $2,055 vs. $1,191; $2,061 vs. $1,166, p< 0.0001) and CHD RE 
cohort ($1,926 vs. $844; $1,535 vs. $850; $1,475 vs. $853, p< 0.0001). Significant cost 
differences were observed between patients with and without new CVEs in both 
cohorts, including inpatient, outpatient, emergency room and pharmacy visit costs 
PPPM, during 1-3 years post-CVE. cOnclusiOns: Healthcare costs for high-risk 
patients with new CVEs remained significantly higher than for matched patients 
Objectives: To estimate acute, short-term and long-term healthcare costs among 
hyperlipidemia patients following a cardiovascular event (CVE). MethOds: This 
retrospective cohort study examined hyperlipidemia patients (≥ 1 medical claim 
and/or ≥ 1 prescription for lipid-lowering therapy) using longitudinal administrative 
claims data from a large commercial US insurer. Those with a CVE and those without 
a CVE were propensity score matched to adjust for differences in demographics, 
comorbidities, and coronary heart disease risk. Qualifying CVEs were MI, ischemic 
stroke, PCI, CABG, unstable angina, TIA or heart failure. Patients were followed from 
index (date of first CVE or a randomly selected date for those w/o a new CVE) until 
the earlier of disenrollment, 8/31/12, or 36 months after the index. Analyses reported 
here are limited to commercially enrolled CVE patients and their matched no CVE 
pair. The payer perspective was taken for all analyses with cost representing the 
total health plan + patient paid amounts. Mean ±SD costs are presented for the 
following periods: acute (days 0-30), short-term (days 31 to 365), 2nd year (days 366-
730) and 3rd year (days 731-1095). Results: The study included 156,679 pairs. Acute 
costs were $23,213±41,561 and largely driven by inpatient costs ($18,040±39,805). 
Acute costs among those with no CVE were significantly less at $799±4,037 (p< 0.001). 
Costs in the short-term were $18,532±48,721 ($6,484±15,948 for no CVE, p< 0.001), 
2nd year costs were $15,335±43,438 ($4,396±13,326 for no CVE, p< 0.001) and 3rd year 
costs were $14,210±38,681 ($2,704±9,783 for no CVE, p< 0.001). cOnclusiOns: Acute 
costs are highest in hyperlipidemia patients with a CVE compared to those without. 
The main driver of costs following a CVE was inpatient hospitalizations. Although 
costs decline in the short- and long-term, costs of patients with CVEs remain high 
for several years compared to hyperlipidemia patients without CVEs.
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Objectives: To quantify the cost savings potential due to a reduction in hos-
pitalizations (all-cause and for worsening HF) for patients with chronic systolic 
HF. MethOds: An economic model was developed to quantify the rates and costs of 
hospitalizations from both the US commercial (< 65 years of age) payer and Medicare 
perspectives in patients with chronic systolic heart failure. Hospitalization rates 
and costs by hospitalization type were taken from US commercial and Medicare 
claims data. The SHIfT trial was used to obtain rate ratios by type for hospitaliza-
tion of patients receiving ivabradine versus placebo on a background of guideline-
suggested drug therapy. A generalized linear model with Poisson distribution and 
log-link function was used to estimate admission rate ratios adjusted for baseline 
beta-blocker use. Results: In the commercial HF population, an annual rate of 
all-cause hospitalization of 1.52 per patient-year (PY) results in a cost burden of 
$46,215/PY; 75% of that cost is from HF-related hospitalizations. The rate ratios and 
95% confidence intervals with ivabradine over the entire trial follow-up were: 0.74 
(0.68-0.80) and 0.89 (0.82-0.96) for HF-related and all-cause hospitalizations, respec-
tively. With ivabradine, a reduction of $9,980/PY in all-cause hospitalization costs 
was estimated in the commercially insured HF population, $8,904 of which was due 
to reductions in HF-related hospitalizations. A higher rate of hospitalization in the 
Medicare population was observed (2.19/PY), but was associated with a lower cost 
burden of $29,982/PY due to lower cost per hospitalization. With the same relative 
risk reduction, ivabradine yielded a $4,627/PY reduction in all-cause hospitaliza-
tion costs in the Medicare population, $3,207/PY of which was due to reductions 
in HF-related hospitalizations. cOnclusiOns: The cost burden of hospitalization 
events is substantial for patients with HF. Reducing the rate of hospitalizations 
with ivabradine may reduce hospitalization costs by $9,980/PY and $4,627/PY for 
the commercially insured and Medicare population, respectively.
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Objectives: To describe the healthcare resource utilization and costs in the year 
following hospitalization for acute ischemic stroke (AIS). The mean lifetime cost 
of AIS is approximately $140,000. With cost estimates projected to increase three-
fold by 2020, it is important to gain a better understanding of the direct economic 
burden of AIS in the US. MethOds: The MarketScan® Commercial Database was 
used to identify non-elderly adults (age 18-64) hospitalized with AIS (index defined 
as first Medicare Severity Diagnosis Related Group 061-066 and confirmatory AIS 
diagnosis (ICD-9-CM: 434.x1)) between January 2009 and December 2012. Patients 
were required to have 12 months of continuous enrollment pre- and post-index. 
Patients with AIS in the year pre-index were excluded. Demographic and clini-
cal characteristics were evaluated at admission and in the pre-index, respectively. 
Direct costs, inpatient length of stay (LOS) and readmissions were described in the 
year post-index. Results: A total of 20,314 patients (age= 54.1 years (standard 
deviation (SD)= 7.9); 57.9% male) met all selection criteria. Approximately one-half 
(46.9%) of patients had baseline hypertension and one-fourth had hyperlipidemia 
(27.2%) and diabetes (25.7%). Total mean costs for the index AIS admission were 
$18,456 (SD= $30,549) with an average LOS of 3.8 days (SD= 4.5). Mean all-cause 
costs in the year after an AIS were $61,354 (SD= $83,048), one-half of which were 
incurred 31-365 days following the incident AIS. One-fourth (24.6%) of patients were 
readmitted within 30 days, 16.6% of those readmitted had a principal diagnosis of 
AIS with an average LOS nearly three times that of the initial hospitalization (10.8 
days (SD= 18.7)). cOnclusiOns: In addition to the substantial costs of the initial 
hospitalization of an acute ischemic stroke, these costs double within the year 
following this event. Given the high cost associated with AIS, new interventions 
reducing either the acute or longer term burden of AIS are needed.
